What Element Biosciences does

Element Biosciences is a private life sciences tools company founded in 2017 in San Diego by three former Illumina executives — CEO Molly He, CTO Michael Previte, and VP Biochemistry Matthew Kellinger. The company develops proprietary DNA sequencing and multiomics platforms based on its core technology, Avidite Base Chemistry (ABC), a proprietary sequencing chemistry that delivers high accuracy (claimed 99.99%, with 93.8% accuracy at 30 bp homopolymers versus 55.7% for Illumina NextSeq 2000) in compact benchtop instruments.

Element's product portfolio spans three instrument lines: AVITI, a benchtop DNA sequencer priced at $289,000 (or $249,000 bundled for 3+ units) with dual random-access flow cells and a lifetime reagent price guarantee at less than $6 per gigabase; AVITI24, the first 5D multiomics system enabling simultaneous detection of RNA, protein, and cell morphology with subcellular spatial co-detection; and VITARI, a high-throughput benchtop system launched in February 2026 at $689,000 capable of delivering a 30X whole genome for $100. The portfolio is supported by Cloudbreak and Trinity sequencing kits, LoopSeq synthetic long-read kits (up to 5 kb acquired via the 2022 Loop Genomics acquisition), Teton CytoProfiling reagents, and the ElemBio Cloud and ElemBio Catalyst software platforms. The forthcoming AVITI Dx Class A IVDR platform, anchored by June 2026 ISO 13485 certification, targets clinical laboratories with availability expected late 2026.

The company generates revenue through a mix of capital equipment sales (instruments), recurring reagent and kit consumables, financing and leasing services through the ElemBio Capital Solutions partnership with DLL, and laboratory services including the Technology Access Program and AVITI Accelerator Grant. Go-to-market combines direct enterprise sales targeting major research institutions and pharmaceutical companies, a global distribution network spanning 40+ countries across North America, EMEA, and Asia Pacific, and an open ecosystem of 20+ validated integration partners across library prep, target enrichment, single-cell, proteomics, and informatics (including 10x Genomics, QIAGEN, Agilent, NEB, Roche, Google DeepVariant, SOPHiA GENETICS, and Olink). Element serves academic research institutions, pharmaceutical and biotechnology companies, clinical research organizations, population genomics programs, and clinical testing laboratories. As of mid-2026, the company has raised over $952 million in cumulative funding across Series A through Series E, with Samsung Electronics as its largest shareholder following the June 2026 Series E investment of $175 million, and achieved a $1.03 billion valuation at its July 2024 Series D.

Name

Element Biosciences

Legal name

Element Biosciences, Inc.

Website

https://elementbiosciences.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

251–500 employees

Short description

Element Biosciences is a private life sciences tools company developing proprietary DNA sequencing and multiomics platforms (AVITI, AVITI24, VITARI) based on its Avidite Base Chemistry, serving academic, pharmaceutical, biotechnology, and clinical research customers across more than 40 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. DNA Sequencing Instruments: Sale of benchtop DNA sequencing instruments including AVITI ($289,000 standard, $249,000 bundled for 3+ units), VITARI ($689,000), and AVITI24. Capital equipment sales with high upfront revenue and ongoing reagent revenue.
2. Sequencing Reagents and Kits: Recurring consumables revenue from sequencing kits and reagents. 300-cycle kit at $1,680, 150-cycle kit at $1,080. Reagent price guarantee for lifetime of AVITI system provides revenue predictability. Includes Cloudbreak, Trinity, LoopSeq, Teton CytoProfiling kits.
3. Financing and Leasing Services: ElemBio Capital Solutions in partnership with DLL provides financing and leasing options for customers wanting to avoid upfront ownership costs.
4. Laboratory Services: Technology Access Program and certified service provider programs for Teton CytoProfiling on AVITI24. Broader lab services supporting customer adoption.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels9 records

Core offering

Element Biosciences develops and manufactures benchtop DNA sequencing instruments and multiomics systems powered by proprietary Avidite Base Chemistry (ABC). The portfolio includes the AVITI benchtop sequencer, AVITI24 5D multiomics platform, and VITARI high-throughput sequencer, along with reagent kits (Cloudbreak, Trinity, Teton CytoProfiling), cloud software (ElemBio Cloud, ElemBio Catalyst), and lab services for genomic, transcriptomic, proteomic, and spatial biology research.

Product overview

Element Biosciences develops a multi-product platform spanning benchtop DNA sequencers and multiomics systems, supported by proprietary reagent kits and cloud-based software. The core portfolio comprises three instrument lines: AVITI (mid-throughput benchtop sequencer, $289,000), AVITI24 (5D multiomics spatial platform integrating DNA/RNA/protein/morphology detection), and VITARI (high-throughput benchtop system capable of $100 genome at 30X coverage, priced at $689,000, shipping H2 2026). These instruments are powered by Element's proprietary Avidite Base Chemistry (ABC) sequencing technology. Consumable reagent kits include Cloudbreak Sequencing Kits (supporting 2×150 to 2×300 read lengths with fastest run times in class) and Trinity Sequencing Kits for targeted workflows, including the Trinity Freestyle open-format variant. Supporting software includes ElemBio Cloud for instrument management, remote monitoring, and AVITI24 custom workflow design, and ElemBio Catalyst for secondary data analysis. AVITI24 enables Direct In Sample Sequencing (DISS) for library-prep-free spatial profiling in tissue. Element is expanding into clinical diagnostics with the forthcoming AVITI Dx (Class A IVDR instrument, expected late 2026). The company serves academic, pharmaceutical, biotechnology, and clinical research customers across more than 40 countries.

Differentiator

Problem solved

Functional benefit

Brands

• AVITI: Benchtop DNA sequencing system offering unprecedented performance, cost, and flexibility
• AVITI24
• AVITI LT
• VITARI
• Cloudbreak
• Trinity
• LoopSeq
• ElemBio Cloud
• ElemBio Catalyst
• Avidite Base Chemistry (ABC)
• Direct In Sample Sequencing (DISS)

Products and services

• AVITI System A benchtop DNA sequencing system with two random-access flow cells offering high-quality, cost-effective sequencing using proprietary Avidite Base Chemistry (ABC). Provides 2x150 paired-end reads, >90% Q30 accuracy, 800M+ reads per flow cell (scalable to 1B+), at $5-$7 per Gb, priced at $289,000.
• AVITI24 The first 5D multiomics system for spatial, single-cell multiomics and high-quality affordable sequencing. Provides subcellular spatial co-detection of RNA, protein, and morphology via ABC Sequencing on a single integrated platform with 24-hour run times and 20 cm² imaging area.
• VITARI A high-throughput benchtop sequencing system — the first benchtop capable of delivering a high-quality whole genome at $100 (30X coverage). Generates up to 10 billion reads or 3 Tb per run in approximately 36 hours. Listed at $689,000, with shipping beginning H2 2026.
• AVITI LT A lower-throughput variant of the AVITI benchtop sequencing system, designed for labs with smaller-scale sequencing needs.
• Cloudbreak Sequencing Kits Proprietary sequencing chemistry kits for the AVITI System featuring Avidite Cloudbreak technology, which reduces run times to under 40 hours for 300-cycle kits and under 24 hours for 150-cycle kits. Supports 2x300 configurations with yields of 1.6B reads (dual-sided) and onboard linear library loading via Elevate adapters.
• Trinity Sequencing Kits Targeted sequencing kits designed to streamline genomic research workflows, offering simplified library preparation for targeted panels. Trinity Freestyle extends the platform with a more flexible, open-format workflow for custom applications.
• Teton CytoProfiling Kits Spatial profiling kits for the AVITI24 system enabling cell paint, protein detection, and Direct In Sample Sequencing (DISS) for multiomic readouts in the same run.
• Elevate Library Adapters Library adapter products supporting onboard linear library loading for AVITI sequencing workflows.
• Adept Library Adapters Library adapter products for AVITI sequencing workflows.
• ElemBio Cloud A customer-facing software portal for AVITI and AVITI24 users that enables instrument configuration, user access management, remote run monitoring, and custom workflow design for AVITI24 multiomics experiments.
• ElemBio Catalyst Secondary analysis software for AVITI sequencing data, providing downstream data processing and interpretation capabilities for genomic workflows.
• Element LoopSeq Long-Read Kits Synthetic long-read sequencing kits providing capabilities on AVITI for highly accurate continuous long reads up to 5 kilobases, enabling amplicon sequencing and full-length 16S microbiome sequencing without a dedicated long-read instrument.
• AVITI Dx Forthcoming Class A IVDR sequencing platform designed to bring the accuracy, throughput, and workflow advantages of the AVITI system to clinical laboratories. ISO 13485 certified as prerequisite for IVD regulatory filings. Expected availability in late 2026 in select countries.

Quantifiable outcome

• 93.8% homopolymer accuracy at 30bp vs 55.7% for Illumina NextSeq 2000
• +8 more outcomes

Named customers10 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability8 records

Feature10 records

Partnerships

20 partnerships are on record, tiered core.

• Myllia BiotechnologycoreStrategic or Co-development Partner · 16 March 2026Collaboration demonstrating successful multimodal optical pooled screening using AVITI24 multiomic system. Validated ability to capture genotype-to-phenotype relationships at scale for drug discovery in oncology, immunology, and metabolic diseases.
• biomodalcoreTechnology or Integration · 23 February 2026biomodal's duet multiomic solutions now compatible with AVITI24 and AVITI sequencing instruments. Validation at University of Minnesota Genomics Center enables complete methylation detection and streamlined end-to-end workflow for cancer, aging, and neurodegenerative disease research.
• SOPHiA GENETICScoreTechnology or Integration · 11 November 2025Partnership to integrate AI-powered analytics with Element's AVITI sequencing systems. Combines SOPHiA's DDM platform with Element's instruments for streamlined data-to-insight workflows, expanding analytical capabilities for laboratories in cancer genomic profiling and precision medicine.
• QIAGENcoreTechnology or Integration · 11 November 2025Partnership for QIAseq targeted library construction chemistries on AVITI system. Validated compatibility of QIAGEN's NGS library prep and target enrichment offerings demonstrating performance, cost, and flexibility integration.
• Virotek BiosciencescoreChannel Partner/ Reseller/ Distributor · 22 October 2025Canada's first commercial lab to deploy AVITI24 for translational genomics research. Enhanced throughput, accuracy, and cost efficiency for genomic research supporting molecular profiling.
• Gene SolutionscoreStrategic or Co-development Partner · 22 April 2025Strategic collaboration leveraging Element's AVITI24 multiomics platform and Gene Solutions' regional network to advance research and clinical applications globally, particularly in prenatal testing and cancer care.
• RevvitycoreStrategic or Co-development Partner · 20 January 2025Partnership for transformation of neonatal genetic testing using Element's AVITI platform. Includes ongoing IVD co-development work with Revvity for newborn screening applications.
• Amazon OmicscoreTechnology or Integration · 15 May 2023Collaboration accelerating data discoveries with Amazon Omics for cloud-based genomic data management and analysis integration.
• OlinkcoreTechnology or Integration · 7 June 2022Collaboration enabling Olink Explore high-throughput proteomics platform on AVITI. Technical proof-of-concept demonstrated high compatibility for combined proteomics and genomics workflows.
• GenooxcoreTechnology or Integration · 1 March 2022Partnership validating AVITI for rare and undiagnosed disease research using whole-genome sequencing. Study with UC San Diego achieved 50% anticipated diagnostic yield using Genoox's Franklin platform.
• Google DeepVariantcoreTechnology or Integration · 28 February 2022Partnership for variant calling analysis using Google DeepVariant deep learning technology. Element-specific machine learning models generated for improved accuracy, especially at lower coverages.
• SentieoncoreTechnology or Integration · 28 February 2022Partnership for variant calling analysis with Sentieon's optimized algorithms. 6-month free license offered to Element instrument customers. Faster and cheaper alternative to industry standard for secondary analysis.
• 10x GenomicscoreTechnology or Integration · 24 February 2022Element became newest member of 10x Genomics' Compatible Partner Program (CPP) across multiple single cell applications. AVITI System validated for seamless compatibility with 10x Genomics' Chromium Single Cell and Visium Spatial platforms.
• Agilent TechnologiescoreTechnology or Integration · 23 February 2022Integration of Element's AVITI System with Agilent's SureSelect target enrichment panels. Validated hybrid-capture target enrichment solutions for detection of SNVs, structural variants, CNVs, fusions, insertions, and deletions.
• Fabric GenomicscoreTechnology or Integration · 23 February 2022Partnership to explore end-to-end clinical application solutions based on AVITI system and Fabric Enterprise clinical interpretation platform. Validated ability to identify pathogenic variants in targeted panels and WGS cases.
• New England Biolabs (NEB)coreTechnology or Integration · 22 February 2022Partnership to launch NEBNext Ultra II kits specifically designed for AVITI System. Combines NEB's library prep technology with Element's sequencing platform for streamlined high-performance workflows.
• Jumpcode GenomicscoreTechnology or Integration · 22 February 2022Partnership validating Jumpcode's CRISPRclean technology on AVITI. Demonstrated 50% increase in genes per cell and additional cell type classification in human blood samples. Enhanced sensitivity and improved resolution for various applications.
• Dovetail GenomicscoreTechnology or Integration · 22 February 2022Validated Dovetail's proximity ligation-based NGS library prep solutions on AVITI. Enables 3D genome architecture capture alongside primary sequence information for epigenetics and chromatin topology applications.
• Watchmaker GenomicscoreTechnology or Integration · 22 February 2022Validated Watchmaker's DNA and RNA Library Prep Kits on AVITI System. Purpose-engineered enzymes and workflow solutions address demanding sample preparation needs.
• RochecoreTechnology or Integration · 22 February 2022Collaboration validating Roche KAPA HyperPlus and KAPA EvoPlus library preparation kits in microbial WGS, human WGS, and human whole-exome applications on AVITI.

Scale indicators10 records

Recent moves7 records

Expansion highlights8 records

Broad incumbents

• Illumina: Illumina dominates the DNA sequencing market with ~80%+ share via the NovaSeq X, NextSeq, and MiSeq lines. It is Element's primary competitor across benchtop and high-throughput segments, the target of Element's competition countersuits, and the standard Element explicitly positions AVITI/VITARI against on price and accuracy.
• MGI Tech: MGI Tech (BGI Group) sells DNBSEQ sequencing platforms and is aggressive on price across Asia-Pacific and emerging markets. MGI competes with Element's benchtop and high-throughput lines, particularly in regions where Chinese vendor pricing and local distribution give MGI structural advantages.
• Thermo Fisher Scientific: Thermo Fisher sells the Ion Torrent sequencing platform and is a major player in NGS sample prep, instruments, and clinical sequencing services. Element's CCO and VP Sales are ex-Thermo Fisher Clinical NGS leaders, and Thermo competes with Element across the sequencing workflow from sample prep through clinical interpretation.

Direct peers

• Ultima Genomics: Ultima's UG100 high-throughput sequencer is explicitly named as a direct competitor in Element's VITARI launch materials, with a $100-genome price point. Both companies are pursuing the same disruptive cost-per-genome strategy against Illumina NovaSeq, making Ultima Element's most direct challenger in the high-throughput segment.
• Singular Genomics: Singular Genomics markets the G4 benchtop sequencing platform targeting similar mid-throughput research customers. It competes head-to-head with Element's AVITI on benchtop footprint, price, and turnaround time, and is part of the same wave of newer entrants challenging Illumina's NextSeq franchise.
• Pacific Biosciences: PacBio is a sequencing platform competitor that sells both long-read (Revio, Sequel) and short-read (Onso) instruments. PacBio's Onso directly competes with AVITI in the benchtop short-read segment, and PacBio's HiFi long reads compete with Element's LoopSeq synthetic long-read capability, making it a multi-front peer.
• Oxford Nanopore Technologies: Oxford Nanopore sells benchtop (MinION, GridION) and high-throughput (PromethION) sequencing systems using nanopore chemistry. It competes with Element across the benchtop-to-high-throughput range, particularly in long-read applications where Element's LoopSeq and the AVITI24 spatial workflow overlap with nanopore's native long reads.

Emerging players

• 10x Genomics: 10x Genomics provides single-cell and spatial genomics assays (Chromium, Visium, Xenium) that are validated to run on Element's AVITI and AVITI24 systems. While 10x is also a partner through the Compatible Partner Program, its Xenium spatial platform competes directly with AVITI24's DISS spatial workflow, making it both ally and competitor.
• Bionano Genomics: Bionano sells the Saphyr optical genome mapping system for structural variant and cytogenomics analysis, complementing rather than directly replacing sequencing. Bionano is an emerging adjacent peer in the broader genomics workflow that customers sometimes bundle with sequencing platforms including Element's.
• GenapSys: GenapSys markets a low-cost, compact electronic sequencing platform targeting decentralized and emerging-market use cases. As an early-stage direct peer in the benchtop/low-cost sequencing segment, GenapSys represents the kind of disruptive entrant Element must out-execute on cost and applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights13 records

Customer concentration

• Xx.com/ElemBio
• Facebookfacebook.com/elementbiosciences
• LinkedInlinkedin.com/company/elembio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Element Biosciences